Purple Biotech Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on July 29, 2026, by Purple Biotech Ltd., a foreign private issuer based in Rehovot, Israel, serves as a notification regarding the scheduling of the Company's Annual General Meeting of Shareholders. The filing does not contain financial results or operational updates for a specific reporting period.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not include financial statements or key performance indicators.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces the upcoming shareholder meeting and incorporates related voting materials by reference.
Guidance, Outlook, and Management Commentary
There is no management commentary, financial guidance, or outlook provided in this text. The filing details the logistics of the Annual General Meeting scheduled for Tuesday, September 8, 2026, at 4:30 p.m. Israel time. It notes that BNY Mellon, the depositary for the American Depositary Shares (ADSs), will distribute a Voting Instruction Form to ADS holders.
Key Facts for Investor Verification
- Meeting Date: Annual General Meeting is set for September 8, 2026.
- Meeting Location: Company offices at 4 Oppenheimer Street, Science Park, Rehovot, Israel.
- Voting Materials: Notice of Meeting, Proxy Statement, Voting Slip for ordinary shares, and Voting Instruction Form for ADS holders are attached as Exhibits 99.1 through 99.3.
- Financial Data: No financial data is present in this specific filing; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.